Guardant's liquid biopsy got FDA clearance as a companion diagnostic for Boehringer's HER2 mutated NSCLC drug, the 27th such indication for Guardant360 CDx and a sign that blood based testing is becoming the only scalable way to reach a 40,000 patient global pool.
A blood test just became the on-ramp for a drug that treats roughly 2 to 4 percent of lung cancer patients. On June 12, 2026, the FDA cleared Guardant Health's Guardant360 CDx liquid biopsy as a companion diagnostic for Boehringer Ingelheim's Hernexeos, according to Fierce Biotech's report on the approval. Hernexeos, known generically as zongertinib, is an oral therapy approved in August 2025 for previously treated non-small cell lung cancer whose tumors carry HER2 tyrosine kinase domain activating mutations, and the new clearance makes the blood test the routine clinical entry point to it.
That sequence matters. Hernexeos is the first FDA-approved oral treatment specifically designed for that molecular subgroup, but the subgroup itself is small and geographically scattered. HER2 TKD activating mutations show up in about 2 to 4 percent of NSCLC cases, which works out to roughly 40,000 patients worldwide. Finding them, at any scale, requires pulling tumor DNA from a routine blood draw rather than scheduling a tissue biopsy at a specialty center. A clinician can now order the Guardant360 CDx test on a blood sample and, if the result flags a HER2 TKD activating mutation, treat the patient with Hernexeos.
This is Guardant360 CDx's 27th companion diagnostic indication, a number the company frames as a sign of growing reach, but the more telling pattern is the kind of patient population each new indication serves. The test is now load-bearing infrastructure for rare-mutation oncology, where the addressable population is too small and too dispersed for tissue-based screening programs to find patients cost-effectively. The cadence matters as much as the single approval: each new indication adds another molecular subtype to a single blood-based workflow that oncologists are increasingly defaulting to when the alternative is invasive sampling that many patients never get.
There are real limits to call out. A companion diagnostic clearance is a regulatory event, not a clinical outcomes event, and the Fierce Biotech coverage notes the approval is reported by the companies and has not been independently confirmed against the FDA approval letter, Guardant filing, or Boehringer release. The 27-indication count is vendor self-reported. Turnaround time for liquid biopsy results still varies by lab and region, and the populations most likely to be missed by any blood-based screening program are the same populations already underserved by specialty cancer care. The structural question the clearance raises is not whether Hernexeos works, which the August 2025 drug approval already addressed, but whether the diagnostic plumbing is fast and equitable enough to deliver candidates to it.
What to watch next is whether the Guardant-Nuvalent companion diagnostic partnership, referenced in related Fierce Biotech coverage, follows the same template, and whether other HER2 TKD inhibitors in development route to their patients through the same blood-based pathway. The Hernexeos indication is the cleanest available test case for a model that depends on liquid biopsy doing the patient-finding for drugs aimed at vanishingly small molecular subgroups.